JP7783834B2 - Ｔｉｅ－２の活性化物質による急性呼吸窮迫症候群の処置方法 - Google Patents

Ｔｉｅ－２の活性化物質による急性呼吸窮迫症候群の処置方法

Info

Publication number
JP7783834B2
JP7783834B2 JP2022569498A JP2022569498A JP7783834B2 JP 7783834 B2 JP7783834 B2 JP 7783834B2 JP 2022569498 A JP2022569498 A JP 2022569498A JP 2022569498 A JP2022569498 A JP 2022569498A JP 7783834 B2 JP7783834 B2 JP 7783834B2
Authority
JP
Japan
Prior art keywords
administration
subject
hours
tie
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022569498A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023526790A5 (https=
JP2023526790A (ja
Inventor
ケビン ピータース，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eyepoint Pharmaceuticals Inc
Original Assignee
Eyepoint Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eyepoint Pharmaceuticals Inc filed Critical Eyepoint Pharmaceuticals Inc
Publication of JP2023526790A publication Critical patent/JP2023526790A/ja
Publication of JP2023526790A5 publication Critical patent/JP2023526790A5/ja
Application granted granted Critical
Publication of JP7783834B2 publication Critical patent/JP7783834B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022569498A 2020-05-21 2021-05-20 Ｔｉｅ－２の活性化物質による急性呼吸窮迫症候群の処置方法 Active JP7783834B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063028317P 2020-05-21 2020-05-21
US63/028,317 2020-05-21
PCT/US2021/033495 WO2021236985A1 (en) 2020-05-21 2021-05-20 Methods of treating acute respiratory distress syndrome with activators of tie-2

Publications (3)

Publication Number Publication Date
JP2023526790A JP2023526790A (ja) 2023-06-23
JP2023526790A5 JP2023526790A5 (https=) 2024-05-27
JP7783834B2 true JP7783834B2 (ja) 2025-12-10

Family

ID=78707586

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022569498A Active JP7783834B2 (ja) 2020-05-21 2021-05-20 Ｔｉｅ－２の活性化物質による急性呼吸窮迫症候群の処置方法

Country Status (7)

Country Link
US (1) US12544362B2 (https=)
EP (1) EP4153237A4 (https=)
JP (1) JP7783834B2 (https=)
CN (1) CN115666651A (https=)
AU (1) AU2021275224A1 (https=)
CA (1) CA3177415A1 (https=)
WO (1) WO2021236985A1 (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012515169A (ja) 2009-01-12 2012-07-05 アケビア セラピューティクス インコーポレイテッド 血管漏出症候群を治療する方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2195958C1 (ru) 2002-02-19 2003-01-10 Центральный научно-исследовательский институт туберкулеза РАМН Способ лечения синдрома острого повреждения легких после расширенных оперативных вмешательств
WO2004075838A2 (en) * 2003-02-21 2004-09-10 Rikshospitalet-Radiumhospitalet Hf Method and compositions for the treatment of meconium aspiration syndrome
WO2005034929A2 (en) 2003-10-10 2005-04-21 Fibrogen, Inc. Tissue remodeling and vascularization
WO2007084136A2 (en) 2006-01-23 2007-07-26 Ony, Inc. Treatment of acute respiratory distress syndrome
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
CA2909080C (en) * 2013-04-11 2022-07-26 Sunnybrook Research Institute Methods, uses and compositions of tie2 agonists
US9381212B2 (en) * 2014-01-10 2016-07-05 Mallinckrodt Hospital Products IP Limited Methods of using inhaled nitric oxide gas for treatment of acute respiratory distress syndrome in children
WO2017100796A1 (en) * 2015-12-11 2017-06-15 SINACA, Academia Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers
CA3137138A1 (en) * 2019-04-18 2020-10-22 EyePoint Pharmaceuticals, Inc. Methods of treating hypertension with activators of tie-2

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012515169A (ja) 2009-01-12 2012-07-05 アケビア セラピューティクス インコーポレイテッド 血管漏出症候群を治療する方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Am J Trop Med Hyg，2015年，Vol. 93, No. 4, Suppl.，p. 76

Also Published As

Publication number Publication date
EP4153237A1 (en) 2023-03-29
WO2021236985A1 (en) 2021-11-25
EP4153237A4 (en) 2024-07-03
US20240299367A1 (en) 2024-09-12
CN115666651A (zh) 2023-01-31
CA3177415A1 (en) 2021-11-25
AU2021275224A1 (en) 2022-10-13
JP2023526790A (ja) 2023-06-23
US12544362B2 (en) 2026-02-10

Similar Documents

Publication Publication Date Title
Lu et al. Comparison of COVID-19 induced respiratory failure and typical ARDS: similarities and differences
US20180133145A1 (en) Methods of treating eosinophilic esophagitis
JP6827948B2 (ja) 呼吸器疾患の治療
US12551469B2 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection
JP2012107047A (ja) 気管支感染症の治療法
JP2023520229A (ja) 製剤
US20230129866A1 (en) Methods of treating respiratory disease with deupirfenidone
US11701355B2 (en) Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
Theodoraki et al. A retrospective comparison of inhaled milrinone and iloprost in post-bypass pulmonary hypertension
CN105324118A (zh) 盐酸兰地洛尔在快速性心律失常的长期治疗中的用途
JP7783834B2 (ja) Ｔｉｅ－２の活性化物質による急性呼吸窮迫症候群の処置方法
AU2020259450A1 (en) Methods of treating hypertension with activators of Tie-2
JP2017507949A (ja) マトリックスメタロプロテイナーゼ９に対する抗体およびその使用の方法
US20230125415A1 (en) Biomarkers for predicting response to il-6 antagonist in covid-19 pneumonia
KR20230018474A (ko) 급성 호흡 곤란 증후군, 천식, 또는 알러지성 비염을 치료하기 위한 제형 및 방법
US20230357418A1 (en) Results of empacta: a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of tocilizumab in hospitalized patients with covid-19 pneumonia
US20250025450A1 (en) Methods of treating interstitial lung diseases and other fibrotic-mediated pulmonary diseases and disorders with deupirfenidone
JP2023553290A (ja) 慢性閉塞性肺疾患、喘息、肺炎、気管支炎、嚢胞性線維症、肺水腫、間質性肺疾患、サルコイドーシス、特発性肺胞線維症、急性呼吸窮迫症候群、および肺動脈性肺高血圧症を治療するための方法および組成物
JP2017514849A (ja) 特発性肺線維症の治療方法
US11471448B2 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia
US20250205268A1 (en) Treatment of viruses with antiviral nucleosides
WO2022235779A1 (en) Methods of administering terevalefim
US20240025991A1 (en) Method for treating pneumonia, including covid-19 pneumonia, with an il6 antagonist
WO2026035705A1 (en) Treating pulmonary hypertension based on novel biomarker
US20220304959A1 (en) Treatment of long haulers syndrome with niclosamide

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240517

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250821

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251031

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251128

R150 Certificate of patent or registration of utility model

Ref document number: 7783834

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350